MONTREAL -- An investigational bispecific antibody for retinal disease achieved faster and numerically greater short-term improvements in visual acuity and retinal anatomy versus faricimab (Vabysmo), a randomized, proof-of-concept trial showed.
Patients randomized to either of two doses of OLN324 had a two-letter improvement in visual acuity versus faricimab at 20 weeks, more rapid improvement in retinal fluid, and faster and numerically greater reductions in pigment epithelial detachment thickness (PED). Durability was comparable as 82% of patients treated with the higher dose of OLN324 went 12 weeks without retreatment, as did 81% of patients assigned to faricimab.
No patient assigned to the investigational angiopoietin 2 (Ang2)/VEGF inhibitor developed intraocular inflammation, retinal vasculitis, occlusive retinal vasculitis, or endophthalmitis, reported David Eichenbaum, MD, of Retina Vitreous Associates of Florida in St. Petersburg, at the American Society of Retina Specialists meeting.
During a discussion, moderator Charles Wykoff, MD, PhD, of Retina Consultants of Texas in Houston, who was a co-author on the study, asked about progress toward finding biomarkers to identify patients who need Ang2 inhibition in addition to VEGF inhibition.
